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ABSTRACT
Background
The gene for preferentially expressed antigen of melanoma (PRAME) has been shown to be
over-expressed in acute promyelocytic leukemia, but its actual incidence and clinical impact are
still unknown.
Design and Methods
We studied PRAME expression at diagnosis using real-time quantitative polymerase chain reac-
tion in 125 patients with acute promyelocytic leukemia enrolled in the Spanish PETHEMA-96
(n=45) and PETHEMA-99 (n=80) clinical trials. In addition, PRAME expression was evaluated
as a marker of disease activity in 225 follow-up samples from 67 patients with acute promye-
locytic leukemia.
Results
At diagnosis, PRAME expression in patients with acute promyelocytic leukemia was significant-
ly higher (p<0.001) than in patients with non-M3 acute myeloid leukemia (n=213) and in
healthy controls (n=10). Furthermore, patients with acute promyelocytic leukemia with high
PRAME expression had a favorable outcome. Thus, the 5-year relapse-free survival was better
in patients with >100-fold PRAME expression (86% vs. 74%; p=0.03), and this cut-off estab-
lished two sub-groups with different relapse-free survival rates among patients with a white cell
count <109/L (5-year relapse-free survival 94% vs. 80%, p=0.01). This effect was similar in
patients with a white cell count >109/L, although differences were not statistically significant.
In multivariate analysis, white cell count >109/L (p<0.001), bone marrow blasts >90%
(p=0.001), and PRAME expression <100-fold (p=0.009) were associated with short relapse-
free survival. Samples at remission showed PRAME levels similar to those in normal controls
while samples at relapse over-expressed PRAME again. Furthermore, 12/13 samples collected
within the 6-month period preceding relapse showed a >10-fold increase in PRAME expression
levels.
Conclusions
Low PRAME expression defines a subgroup of patients with acute promyelocytic leukemia with
a short relapse-free survival. This marker could be useful as a secondary marker for monitoring
patients with acute promyelocytic leukemia.
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Introduction
Preferentially expressed antigen of melanoma
(PRAME) was identified as a HLA-A24–restricted anti-
gen peptide presented to an autologous tumor-specific
cytolytic T lymphocyte clone derived from a mela-
noma cell line.1 The PRAME gene encodes a putative
protein of 509 amino acids with a function that
remains unknown. Most normal tissues do not express
PRAME but weak expression has been observed in
testis, placenta, endometrium, ovary and adrenal
glands.2 By contrast, this tumor-associated antigen is
frequently expressed in several solid tumors such as
melanomas (88% of primary lesions), non-small cell
lung carcinoma, breast carcinoma, renal cell carcino-
ma, head and neck cancer, Wilms’ tumor and
Hodgkin’s lymphoma.2,3 PRAME is also expressed in
17-42% of acute lymphoid leukemias (ALL) and 30-
64% of acute myeloid leukemias at diagnosis,3-8 as well
as in chronic leukemias.9
In solid tumors, PRAME overexpression is associated
with a more advanced tumor stage, increased probabil-
ity of metastasis and a poor clinical outcome.1,2,10,11 By
contrast, preliminary data suggest that high PRAME
RNA levels correlate with good prognosis and pro-
longed survival in both adult4 and childhood AML,5 as
well as pediatric acute lymphoid leukemias.8 Further-
more, this high expression has been associated with
the presence of favorable translocations, such as t(8;21)
and t(12;21).3,4 Given this particular tumor-specific
expression, several authors have suggested that
PRAME could be useful as a target for monitoring min-
imal residual disease (MRD) in acute leukemias.3-6,12-14
In the largest published series of MRD evaluation,
Steinbach et al.12 showed, in 26 cases of childhood non-
M3 AML, that PRAME expression decreased to control
levels in patients who achieved a continuous complete
remis-sion. In addition, a rise in the expression level
was observed in patients who eventually relapsed.12
Although some reports found higher PRAME expres-
sion when the t(15;17) was present, these data were
based on small numbers of patients with acute
promyelocytic leukemia (APL).3,4,13 The clinical impact
of PRAME on the outcome of patients with APL has
not, however, been evaluated yet. The aim of this
study was to analyze PRAME expression and its rela-
tionship to survival and prognosis in a large series of
uniformly treated APL patients, as well as to evaluate
its potential value as a surrogate marker for MRD
investigations.
Design and Methods
Patients
We analyzed pre-treatment bone marrow samples
from 125 adult APL patients enrolled in the Spanish
PETHEMA-9615 (n=45) and PETHEMA-9916 (n=80)
treatment trials. Both protocols included an induction
phase with all trans retinoic acid (ATRA) plus idaru-
bicin and three consolidation courses with idarubicin,
mitoxantrone and idarubicin, followed by a mainte-
nance phase with ATRA, methotrexate and mercap-
topurine for 2 years.15 The PETHEMA-96 protocol was
designed with a unique consolidation arm. By con-
trast, in the PETHEMA-99 protocol, the consolidation
phase was modified by including ATRA plus higher
doses of idarubicin for intermediate or high-risk
patients16 [white blood cell (WBC) count ≥10×109/L
and/or platelet count <40×109/L]. The diagnosis of APL
was confirmed according to standard criteria.16 After
obtaining written consent, bone marrow samples were
taken from ten healthy donors and used as controls for
gene expression analysis. Additionally, 213 non-M3
bone marrow samples taken at diagnosis were ana-
lyzed as a reference group for PRAME expression.
Informed consent to the use of biological samples and
clinical data was obtained from all patients.
RNA extraction and cDNA synthesis
Total RNA was obtained from unfractionated bone
marrow samples (taken at diagnosis with >70% blast
cells) using the acid guanidium thiocyanate-phenol
chloroform extraction method, as previously
described.17 Reverse transcription was performed using
the Europe against Cancer Group (EAC) protocol.18
Briefly, 1 µg of total RNA was added to a 20-µL vol-
ume containing random hexamers as primers and 100
U of SuperScript RNase H reverse transcriptase
(Invitrogen, CA, USA). The mixture was incubated at
42°C for 60 min, followed by 3 min at 99°C and 2 min
at 4°C. Aliquots were stored at -80ºC prior to further
analysis.
Quantification of PRAME expression 
PRAME expression was quantified using the 7900
HT Fast Real-Time PCR System and TaqMan Gene
Expression Assays (Applied Biosystems, Foster City,
CA, USA) according to the manufacturer’s instruc-
tions. The cycle number at which the reaction crossed
an arbitrarily placed threshold (CT) was determined
and the relative expression of PRAME regarding a
housekeeping gene (ABL1), used as a control of RNA
quality, was calculated using the equation 2–∆∆Ct where
∆CT = CTPRAME – CTABL1 and ∆∆CT= ∆CTsample –∆CTHealthy
BM (median).19 In order to carry out the ∆∆CT correction,
we selected the median ∆CT value obtained in bone
marrow samples from ten healthy donors. PRAME
expression values were thus expressed as relative units
(RU), where one RU is equivalent to the PRAME
expression of the healthy donor bone marrow sample
with the median ∆CT value. The assay ID were: ABL1,
Hs00245445_m1, and PRAME, Hs00196132_m1.
Quantification of the PML-RARA fusion gene
Absolute quantification of PML-RARA transcripts
was carried out by real-time quantitative polymerase
chain reaction (RQ-PCR) using an ABI PRISM 7700
DNA Sequence Detection System (Applied
Biosystems, Foster City, CA, USA) according to the
EAC protocol.18,20 PML-RARA transcript copy numbers
were assessed in 5 µL (100 ng) of cDNA, using com-
mercial plasmids (IpsoGen Laboratories, Marseille,
C. Santamaria et al. 
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France) to construct the standard curve. The house-
keeping gene Abelson-1 (ABL1) was selected as a con-
trol gene for RNA expression as previously reported.21
A non-amplification control, containing RNA from a
healthy donor and a non-template control with dis-
tilled water instead of human cDNA were included in
each assay. All samples were analyzed in triplicate and
results are reported according to EAC guidelines as the
normalized copy number, which is derived by multi-
plying the PML-RARA copy number/ABL1 copy num-
ber ratio by 10000.
Detection of FLT3 mutation
FLT3-ITD was examined by amplification of the jux-
tamembrane region spanning exons 14 and 15 with
primers 11F and 12R, using qualitative PCR22 and
Genescan analysis.23 The up-stream primer in this lat-
ter approach was fluorescently labeled with 6-FAM to
allow sizing of all products (Model 3130 Genetic
Analyzer, Applied Biosystems).
Statistical analysis
All tests were carried out using the SPSS 15.0 pro-
gram (SPSS, Chicago, IL, USA). For univariate analyses,
the χ2 and Student’s t tests were performed to evaluate
factors associated with PRAME expression. Relapse-
free survival (RFS) was defined as the time between
the achievement of complete remission and the time
of the relapse or the last follow-up. Overall survival
was defined as the time between the moment of diag-
nosis and death or the last follow-up. The probabilities
of RFS and overall survival were calculated using the
Kaplan-Meier method and compared using the log-
rank test.24 RFS was estimated taking hematologic
relapse as a censored event. Continuous variables were
dichotomized according to either the median value or
relapse-risk criteria described by Sanz et al.37 The
impact of multiple predictor variables on RFS was
assessed by multivariate analysis according to the Cox
regression model.25
Results
Efficiency of PRAME RQ-PCR
The efficiency of the quantification method for
PRAME and ABL1 was examined by constructing stan-
dard curves made using cDNA from five APL bone
marrow samples that were strongly positive for both
markers with a 10-fold dilution in distilled water (1 to
10-4). Linear correlations between CT values and
expression levels were obtained for PRAME and ABL1,
with median correlation coefficients of 0.996 (range
0.995 to 0.998) and 0.998 (range 0.997 to 0.999),
respectively. The median value of amplification effi-
ciency was 95.71% (range, 88.65 to 104.31%) for
PRAME and 92.31% (range, 87.42 to 105.98%) for
ABL, indicating that the 2–∆∆Ct method used in our
study for evaluating PRAME expression was indeed
applicable.
PRAME expression in APL at diagnosis
PRAME expression was assessed in bone marrow
samples taken at diagnosis from 125 APL patients
treated within PETHEMA multicenter trial protocols.
For the 2–∆∆Ct method we used bone marrow samples
from ten healthy volunteers as a calibrator. The medi-
an ∆CT (CTPRAME-CTABL) value in healthy samples was
12.06 (range, 9.51 to 15.75). For APL samples, the
median ∆Ct value was 4.48 (range, -1.75 to 11.63).
Accordingly, the median PRAME expression was 1.0
RU (range, 0.1-5.8) for healthy donors and 191.0 RU
(range, 1.3-14301.6) for APL patients. As a reference,
we also tested PRAME levels in 213 cases of newly
diagnosed AML without t(15;17). In these latter
patients, PRAME expression levels were significantly
lower than in the APL cases (median value of 10.1 RU;
range, 0.1-59531.2; p<0.001) (Figure 1). It is worth not-
ing that the median PRAME value of non-M3 AML
samples corresponds to the 15th percentile of the APL
samples.
Characteristics of APL patients and PRAME
expression
The main clinical and biological features of the 125
APL patients are summarized in Table 1. To define low
and high PRAME expression in the series, we selected
a cut-off value of 100 RU (2 logs). This cut-off was
chosen because it represented the 10-fold level of the
highest value observed in normal bone marrow sam-
ples and it was near to the median value in APL sam-
ples.
When we compared the clinical and biological char-
acteristics of the two sub-groups of APL patients
defined according to PRAME expression levels (low
and high), no significant differences were observed,
except for a trend towards a higher hemoglobin level
(p=0.059) within the high-expression group than in the
PRAME in acute promyelocytic leukemia
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Figure 1. PRAME expression at diagnosis in APL and in patients
with other AML. PRAME levels were estimated with the 2–∆∆Ct
method, using ABL1 as the control gene and bone marrow sam-
ples from ten healthy donors as calibrators. This latter group is
also shown as a reference point. A significant difference was
observed between all groups (*p<0.001).
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low-expression group. It should be noted that the
WBC and platelet counts as well as the PML-RARA
normalized copy number were similar in both groups
(Table 1).
PRAME expression according to response to therapy
and relapse status
Of the 125 evaluated APL patients, 111 (88.8%)
achieved complete remission after induction treatment
(median 34 days after diagnosis; range, 22-88 days).
The remaining 14 patients died during induction treat-
ment due to hemorrhage (n=7), therapy-related infec-
tion (n=6) or ATRA syndrome (n=1) at a median of 14
days after diagnosis (range, 1-29 days). Regarding
PRAME expression, no statistically significant differ-
ence was observed between patients who achieved
complete remission (median 184.3 RU; range, 1.3-
14301.6) and patients who died during induction ther-
apy (median 460.6 RU; range, 7.0-11764.8; p=0.502). 
Among patients achieving complete remission, we
investigated PRAME RNA levels in order to discern
whether these levels were different between patients
who relapsed later (n=16) and those who did not
(n=95). Interestingly, patients in continuous complete
remission had significantly higher PRAME expression
(median 207.6 RU; range, 1.3-14301.6) at diagnosis
than had those patients who eventually relapsed
(median 39.8 RU, range 1.5-5060.1; p=0.05).
Relapse-free survival and overall survival
When we compared the RFS of patients with low and
high PRAME expression levels, defined according to the
threshold previously mentioned (100 RU), we observed
that the latter group of patients had a significantly
C. Santamaria et al. 
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Table 1. Clinical and biological characteristics of acute promyelo-
cytic leukemia patients at diagnosis (n=125), divided according to
PRAME expression.
Parameter PRAME expression PRAME expression p
≤100 RU (n=53) >100 RU (n=72)
Age, years, 45 35 0.096
median (range) (12-76) (9-81)
Sex, Male, n (%) 30 (56.6) 43 (59.7) 0.434
WBC, ×109/L, 2.6 2.6 0.238
median (range) (0.3-97.0) (0.4-146.8)
Hemoglobin, g/dL, 9.0 10.0 0.059
median (range) (6.0-14.6) (6.5-15.3)
Percentage of PB blasts, 36 38 0.945
median (range) (0-100) (0-100)
Platelets, ×109/L, 26 22 0.502
median (range) (3-183) (7-158)
Percentage of BM blasts, 90 88 0.827
median (range) (70-100) (70-100)
PML/RARA NCN1, 3737 2934 0.728
median (range) (827-15587) (839-19750)
PML/RARA isoform, n (%):
Bcr1, n=77 37 (69.8) 40 (55.6) 0.256
Bcr2, n=5 2 (3.8) 3 (4.2)
Bcr3, n=43 14 (26.4) 29 (40.3)
FAB classification, n (%):
M3, n=94 42 (79.2) 52 (72.2) 0.493
M3v, n=31 11 (20.8) 20 (27.8)
FLT3-ITD, n (%):
No, n=82 38 (71.7) 44 (61.1) 0.298
Yes, n=43 15 (28.3) 28 (38.9)
Treatment protocol
PETHEMA 96, n=45 17 (32.1) 28 (38.9) 0.276
PETHEMA 99, n=80 36 (67.9) 44 (61.1)
Relapse-risk groupa, n (%)
Low risk, n=26 15 (28.3) 11 (15.3) 0.172
Intermediate risk, n=64 26 (49.1) 38 (52.8)
High risk, n=35 12 (22.6) 23 (31.9)
Consolidation treatment armb, n (%) 
Standard consolidation 25 (47.2) 36 (50.0) 0.448
Reinforced consolidation 28 (52.8) 36 (50.0)
+ ATRA (PETHEMA 99)
Response to induction treatment, n (%):
Complete remission, n=111 48 (90.6) 63 (87.5) 0.406
Death during treatment, n=14 5 (9.4) 9 (12.5)
ATRA syndrome, n (%)
Absent, n=91 39 (73.6) 52 (72.2) 0.516
Indeterminate/present, n=34 14 (26.4) 20 (27.8)
NCN: normalized copy number; FAB: French-American-British; PB: peripheral
blood; BM: bone marrow; aaccording to Sanz et al., 2000.37 bAccording to Sanz et
al., 2004.15,16 This stratification was used only in the PETHEMA 99 protocol.  
Figure 2. Relapse-free survival (A) and overall survival (B) of APL
patients divided according to PRAME expression levels at diagno-
sis. Only patients who survived beyond the 34th day are included
in this analysis.
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longer RFS (RFS rates of 86% versus 74% at 5 years,
p=0.031; Figure 2A). We evaluated the impact of the
main biological and clinical features of patients on RFS
using the Kaplan-Meier model as a univariate approach
(Table 2). Multivariate analysis for RFS was carried out
including the parameters with significant differences in
the univariate analysis: WBC counts, PRAME expression
level and bone marrow blasts. Only two of these vari-
ables were selected as having an independent prognostic
value for a shorter RFS: WBC >10×109/L (p=0.003) and
PRAME expression <100 RU (p=0.011). 
In APL, the number of WBC has a marked prognostic
impact and may determine treatment choices.26-29
Following a recent analysis by Adès et al. comparing the
French-Belgian-Swiss and PETHEMA results,29 we want-
ed to investigate the prognostic influence of the main
clinical and biological features described in Table 2 in
patients with WBC<10×109/L or WBC ≥10×109/L. In
patients with low WBC, only PRAME expression (100
RU cut-off) could define two subgroups with significant-
ly different RFS at 5 years (80% vs. 92% in low and high
PRAME expression group, respectively; p=0.032; Figure
3A). The Kaplan-Meier curves were not statistically sig-
nificantly different between subgroups by any of the
other clinical and biological parameters. There were few
patients (n=22) in the group with a high WBC count, so
it is not surprising that there were no parameters associ-
ated with statistically significant differences in risk of
relapse. Regarding the 100 RU cut-off, the two sub-
groups showed different RFS curves, but the differences
were not statistically significant (p=0.231) (Figure 3B).
Because all deaths during induction therapy in the
PRAME in acute promyelocytic leukemia
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Table 2. Influence of the clinical-biological characteristics of acute
promyelocytic leukemia patients at diagnosis on their relapse-free
survival (RFS).
n 5-year RFS Univariate Multivariate
WBC at diagnosis 
(×109/L)a
≤10 89 87% 0.002 0.003
>10 22 58%
PRAME expression (RU) 
≤100 48 74% 0.031 0.011
>100 63 86%
Bone marrow blasts at diagnosis (%)b
≤86 56 92% 0.008 0.076
>86 55 69%
FAB classification 
M3 88 84% 0.096 −
M3v 23 71%
Peripheral blood blasts at diagnosis (%)b
≤37 55 86% NS −
>37 56 75%
Platelet count at diagnosis 
(x109/L)a
≤40 83 83% NS −
>40 28 76%
Sex
Male 64 79% NS −
Female 47 81%
Age (years)b
≤39 56 81% NS −
>39 55 83%
PML/RARA
(Normalized copy number)b
≤3093 56 77% NS −
>3093 55 85%
PML/RARA isoform
Bcr1 70 76% NS −
Bcr2 5 80%
Bcr3 36 89%
Hemoglobin (g/dL)b
≤9.5 55 83% NS −
>9.5 56 79%
FLT3-ITD, n (%):
No 80 84% NS −
Yes 31 73%
Treatment protocol 
PETHEMA 96 40 81% NS −
PETHEMA 99 71 82%
Consolidation treatment armc, n (%) 
Standard consolidation 56 82% NS −
Reinforced consolidation 55 81%
+ ATRA (PETHEMA 99)
ATRA syndrome
Absent 84 80% NS −
Indeterminate/present 27 83%
NS: not statistically significant, p>0.1. aDichotomization based on criteria for
high-risk patients from Sanz et al., 2000.37 bDichotomization based on median
value. cAccording to Sanz et al., 2004.15,16 This stratification was used only in the
PETHEMA 99 protocol.
Figure 3. Relapse-free survival of APL patients based on PRAME
expression among patients with a WBC count at diagnosis
<10×109/L (A) or ≥10×109/L (B) following the criteria used by
Ades et al., 2008.26
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present series were due to early infectious or hemor-
rhagic complications and ATRA syndrome rather than to
progressive disease, which is a competing risk in evalu-
ating leukemia-related mortality, we carried out a land-
mark analysis beyond day 34 (the median day for
achieving a response evaluation). In the analysis of the
remaining patients we observed that those with high
PRAME expression had a higher 5-year overall survival
rate compared to patients with low PRAME expression
(85.6% versus 74.4%, Figure 2B), although the differ-
ence did not reach statistical significance (p=0.103). 
PRAME vs. PML-RARA fusion transcript expression
We analyzed 225 follow-up bone marrow samples
from 67 patients who achieved complete remission: 53
patients who maintained a continuous complete remis-
sion and 14 patients who eventually relapsed. The fol-
low-up for patients remaining in complete remission
(median 3.13 years, range 0.5 to 10.6) was virtually the
same as the follow-up for patients who eventually
relapsed (median 3.17 years, range 1.3 to 11.3, p=0.551).
When we compared the reduction of PRAME expression
with that of PML-RARA expression from diagnostic to
post-induction samples, a strong correlation was
observed between the levels of expressions (Pearson’s
correlation coefficient of 0.689, p<0.001). We also ana-
lyzed both MRD markers in samples from patients who
relapsed, finding a similar expression patterns between
PRAME and PML-RARA in all of them. The evolution of
these two markers is illustrated in Figure 4 (A-E) which
shows five representative patients who eventually
relapsed, together with one case who remained in con-
tinuous complete remission (F). In four relapsed patients,
all the samples taken within 6 months before relapse
showed an increase in at least one of the two markers to
above 10 normalized copy numbers or 10 RU. The fifth
patient (Figure 4E) was the only case who relapsed with
no PRAME expression or PML-RARA increase (false-neg-
ative case). None of the three patients in continuous
complete remission with a sample false-positive for
MRD during maintenance and beyond (i.e. Figure 4F)
showed either PRAME expression >10 RU or PML-RARA
>10 normalized copy number in subsequent analyses.
C. Santamaria et al. 
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Figure 4. Comparison of minimal residual disease
evaluated by PML-RARA and PRAME expression.
Expression of PML-RARA (dotted lines) and
PRAME (continuous lines) in follow-up samples
from five patients (A-E) who relapsed and one
patient (F) in continuous complete remission with
one false-positive sample (open arrow). Relapses
are indicated as closed arrows. Samples analyzed
within 6 months before relapse are indicated as
triangles. PML-RARA is expressed as normalized
copy number on a log-scale and PRAME is
expressed as a result of the 2–∆Ct equation (log-
scale). 
Figure 5. PRAME-based evaluation of minial residual disease at
different stages of disease. Patients in continuous complete
remission (CCR) and patients who eventually relapsed were evalu-
ated at diagnosis (DX), post-induction (PI), post-consolidation (PC),
during maintenance therapy (MT) and out of therapy (OT). As
regards patients who relapsed, we analyzed 13 pre-relapse sam-
ples (pre-R) during MT (n=9) and OT (n=4), which were collected
within the 6-month period before relapse, as well as 14 samples
taken during the relapses. Empty boxes correspond to patients in
CCR, who had not relapsed at the time of evaluation (always >1
year of follow-up). Solid boxes correspond to patients who eventu-
ally relapsed. 
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PRAME expression and tumor burden evolution
Upon analyzing PRAME expression during different
phases of therapy, a rapid decrease was observed from
diagnosis to post-induction and post-consolidation
treatment. However, there were no statistically signif-
icant differences in these reductions between patients
in continuous complete remission and patients who
eventually relapsed (Figure 5), indicating that the
kinetics of this parameter has no predictive value for
relapse detection at these two time-points. 
Once the consolidation treatment was concluded,
virtually all samples from patients in continuous com-
plete remission continued to show very low PRAME
expression levels during the maintenance phase (medi-
an 0.25 RU; range, 0-18) and out of treatment (median
2.7 RU; range, 0-11). Only three out of 70 samples
(4.3%) from patients in continuous complete remis-
sion showed PRAME expression >10 RU during main-
tenance therapy and beyond. These were considered
as false positive results, since all subsequent samples
(at least two) had PRAME expression <10 RU (n=9,
median value 0.4; range, 0-6) and none of patients
relapsed (follow-up after the positive sample of 10, 22
and 27 months). By contrast, 11 out of 13 samples
taken within 6 months preceding relapse (median 72;
range 22, to 173 days) from patients who eventually
relapsed had PRAME expression >10 RU (median 18.2
RU; range, 1.9 to 150.0). 
Discussion
In this study we evaluated the biological and prog-
nostic significance of PRAME expression in 125
patients with APL and demonstrated that overexpres-
sion of this tumor-related antigen is associated with a
better outcome and longer RFS. In addition, the RNA
levels of PRAME can be a useful method for monitor-
ing MRD, since levels of expression are reduced during
complete remission and increased several months pre-
ceding relapse. 
High PRAME levels were initially correlated with an
advanced tumor stage and poor clinical outcome for
several solid tumors such as non-small cell lung, breast
and renal cell carcinoma, Hodgkin’s lymphoma,
medulloblastoma and melanomas.1,2,10,11 By contrast, in
hematologic neoplasias such as AML and acute lym-
phoid leukemia preliminary reports suggest that high
PRAME expression is associated with a favorable prog-
nosis.4,5,8 Only two previous studies have indicated
that PRAME levels may be higher in AML patients
with t(15;17) than in the rest of the AML subtypes;
however, both studies only evaluated a limited num-
ber of t(15;17) AML cases using either conventional
semi-qualitative RT-PCR (n=11)3 or gene expression
arrays (n=12).30 When these latter patients were reana-
lyzed using the SYBR Green RQ-PCR approach, a cor-
relation between high expression of PRAME (defined
as the median expression across all AML samples) and
t(15;17) AML was observed.4
However, the authors argued that this correlation
might have been secondary to its correlation with
favorable cytogenetics and they merely observed a
trend towards longer overall survival in cases with
higher PRAME expression.4 Based on a large cohort of
APL patients, our data demonstrate that PRAME
expression is an independent prognostic factor in APL
since its over-expression is associated with prolonged
RFS. Moreover, PRAME level contributes to defining
two prognostic sub-groups within low-risk APL
patients according to whether their WBC count is
above or below 10×109/L.26-29
The biological explanation of why high PRAME
expression is associated with a better prognosis is
unclear. PRAME has been described to be a repressor
of retinoic acid signaling, capable of inhibiting retinoic
acid-induced differentiation, growth arrest and cas-
pase-dependent apoptosis in F9 mouse embryonic car-
cinoma cells.31 Knock-down of PRAME by RNA inter-
ference in the retinoic acid-resistant A375 human
melanoma cell line restores both retinoic acid receptor
signaling and sensitivity to the antiproliferative effects
of retinoic acid.31 However, some authors have shown
that this effect could be tissue-specific, since PRAME
expression is not associated with down-regulation of
retinoic acid signaling in cells from primary AML.32
Furthermore, Tajeddine et al.33 demonstrated that
PRAME overexpression can induce caspase-independ-
ent cell death in CHO-K1 and HeLa cell lines. In addi-
tion, the repression of PRAME expression by a short
interfering RNA increases the tumorogenicity of the
K562 leukemic cell in BALB/c nude mice.33 These latter
findings would be fully concordant with a presumed
beneficial effect of PRAME expression in the prognosis
of APL. 
Traditionally, MRD in APL patients is evaluated
using levels of PML-RARA.18,20,34,35 In the post-induction
phase, about one half of the patients in complete
remission after ATRA plus chemotherapy, remain pos-
itive for PML-RARA in the bone marrow and this eval-
uation is clinically not informative. By contrast, studies
carried out after completion of consolidation treat-
ment are extremely relevant since a positive PML-
RARA test is strongly predictive of relapse.20,28,34,36 In our
series, RNA levels of PRAME at diagnosis were rela-
tively lower than those of PML-RARA, but the kinetics
of both transcripts after therapy seemed to be similar.
PRAME levels in both the post-induction and post-con-
solidation phase did not have any prognostic impact.
By contrast, in follow-up samples during maintenance
treatment and out of therapy, we observed that an
increasing level of PRAME was associated with
impending relapse. 
Accordingly, our results show that APL patients with
a PRAME level 10-fold higher than normal values dur-
ing maintenance therapy and beyond are at high-risk
of relapse. PRAME and PML-RARA expression are
strongly correlated and results after therapy were con-
cordant, since a result of >10 normalized copy number
during this period was almost equivalent to an imme-
diate relapse.20 However, it is unclear whether PRAME
RNA levels give information additional to that provid-
ed by PML-RARA expression, suggesting that PRAME
could be used only as a secondary marker during the
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follow-up of APL. 
In conclusion, our data demonstrate that PRAME is a
suitable indicator of prognosis in APL, since overex-
pression at diagnosis is associated with a better out-
come and the levels were able to identify two sub-
groups with significantly different RFS within low-risk
APL patients (i.e. those with a WBC<10×109/L). 
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